HomeDRUG • NASDAQ
add
Bright Minds Biosciences Inc
Nakaraang pagsara
$89.90
Sakop ng araw
$89.00 - $92.30
Sakop ng taon
$23.18 - $123.75
Market cap
1.20B CAD
Average na Volume
168.41K
P/E ratio
-
Dividend yield
-
Primary exchange
CNSX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (CAD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 6.74M | 325.10% |
Net na kita | -7.57M | -15,349.58% |
Net profit margin | — | — |
Kita sa bawat share | -0.97 | -9,800.00% |
EBITDA | — | — |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CAD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 89.05M | 53.80% |
Kabuuang asset | 90.88M | 55.62% |
Kabuuang sagutin | 1.60M | 179.80% |
Kabuuang equity | 89.28M | — |
Natitirang share | 9.79M | — |
Presyo para makapag-book | 7.84 | — |
Return on assets | -19.23% | — |
Return on capital | -19.65% | — |
Cash Flow
Net change in cash
| (CAD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -7.57M | -15,349.58% |
Cash mula sa mga operasyon | -5.82M | -289.18% |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | 13.39M | -74.27% |
Net change in cash | 6.14M | -88.23% |
Malayang cash flow | -4.01M | -339.54% |
Tungkol
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Itinatag
2017
Website
Mga Empleyado
26
